Who Paid My Doc
Prevnar 20
Biological Vaccines
NDC 0005-2000-02
General payments
$5,435,005
Research payments
$15,453,138
Through program year 2025, $5,435,005 in general payments and $15,453,138 in research payments were reported against Prevnar 20 (Vaccines).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,883,258 | 63,435 |
| 2025 | Research | $5,719,062 | 319 |
| 2024 | General | $1,467,618 | 62,005 |
| 2024 | Research | $3,696,394 | 252 |
| 2023 | General | $1,234,039 | 52,397 |
| 2023 | Research | $2,253,537 | 258 |
| 2022 | General | $848,316 | 34,474 |
| 2022 | Research | $3,783,195 | 1,253 |
| 2021 | General | $1,773 | 101 |
| 2021 | Research | $951 | 4 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 154 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
212,412 general · 2,086 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.